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ABSTRACT 
The Morbillivirus genus includes measles virus (MV), peste des petits ruminants virus 
(PPRV) and rinderpest virus (RPV). Although preventive vaccines are available against 
these three viruses, efficient therapeutics for virus control under emergency situations 
are desirable. Inhibition of morbillivirus replication can be acbieved by post-
transcriptional silencing of the nucleoprotein (N) gene by RNA interference (RNAi). 
The viral N protein, a well conserved protein among the genus, plays a central role in 
the replication of the virus. Using a comprehensive siRNA-based screening of the 
conserved sequences of the N gene, we have identified, three cornmon positions on the 
N gene, for the design of siRNA evenly effectives for PPRV, RPV and MV. siRNA 
silencing resulted in more than 80% decrease of the viral replication in infected Vero 
cell , as sbown by real-time quantitative PCR, flow cytometry and virus titration. In a 
second step, a recombinant replication-defective buman type 5 adenovirus (Ad-5) 
encoding one of the functional sequences directed against the N gene of PPRV was 
constructed and shown to reduce the PPRV replication in vitro. These results illustrate 
that adenovirus vector could be a prornising candidate for the development of siRNA 
antiviral treatments against morbilliviruses. 
INTRODUCTION 
RNA interference (RNAi) is a natural process whereby introduction of 
double-stranded RNA (dsRNA) into cells results in degradation of 
homologous mRNA and, consequently, post-transcriptional gene 
silencing. Specific inhibition of virus genes by RN Ai can be triggered by 
the cellular introduction of synthetic 21- to 25-nucleotide duplexes of 
RNA (siRNA) as was obtained to foot and mouth disease virus (1), 
influenza virus (2), HIV (3) and human hepatitis virus (4). In this study, 
we report on the identification of three conserved loci in nucleoprotein 
gene of PPRV and RPV which can be targeted for inhibition virus 
replication by RNA interference. One of these loci was also effective on 
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MV. As indicators of siRNA functionality, we have measured viral RNA 
and viral protein, the formed infectious particles as well as cytopathic 
effects induced in infected cell cultures. 
MA TERIALS AND METHODS 
Conserved regions were identified on multiple alignments of the N gene 
sequences of all morbilliviruses within which three conserved loci were 
selected. Nineteen base-long siRNAs covering these loci were 
synthesized (Ambion). Vero cells were transfected with 100, 50, 25 and 
12.5nM of siRNAs and Lipofectamine 2000 (lnvitrogen) using usual 
methodology. Twenty-four hours after transfection, cells were infected 
by using a MOI of 0.1 of PPRV, RPV or MV and 4 days later, the siRNA 
silencing effect was evaluated. In a second step of this work, an 
adenovirus vector containing the siRNA sequence NPPRVl (Ad-
shRNANl) was constructed to be tested in vivo. To this end, we have 
used the BLOCK-iT Adenoviral RNAi Expression System (Invitrogen ™) 
according to manufacturer's instructions. Firstly, the knockdown capacity 
of the Ad-shRNANl was verified in infected Vero cell cultures transduced 
with the Ad-shRNANl (MOI of 80) and infected by PPRV (MOI of 0.1) 
after 80 hours. A kinetic analysis of PPRV multiplication in these cell 
cultures has been carried out through virus titration of cell suspension 
samples collected after different hours post-infection. 
RESULTS 
The results demonstrate that the siRNA targeting the conserved locus 1 
(position 480-498) of PPRV severely inhibited the virus multiplication. 
The reduction in N PPRV protein expression assessed by flow cytometry 
was over 90% (Fig. 1). The production of PPRV N transcripts and PPRV 
progeny was efficiently shut down 100- and 10,000- fold, respectively, as 
demonstrated by real time PCR and virus titration (Fig. 2A). Afterwards, 
this locus efficiently silenced on PPRV was evaluated by flow cytometry 
on RPV and MV, using siRNAs homologous to the N gene of these 
viruses. The siRNA NRPVl and NMVl markedly inhibited the 
replication of the corresponding viruses as confirmed by the decrease in 
N protein expression of 90% and 70%, respectively (Figure 1 ). 
Additionally, we have demonstrated that siRNAs NPPRV6, NPPRV7, 
NRPV6 and NRPV7 targeting two other conserved loci of N gene of 
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PPRV and RPV (loci 6 and 7, positions 741-759 and 899-917, respecti-
vely) clearly inhibited the replication of the viruses as assessed by the 
marked decrease in viral protein, with a maximum of 87% (Figure 1 ), a 
reduction of 100- to 1.000-fold in PPRV and RPV titers and 10- to 100-
fold in PPRV and RPV RNA copy number, respectively (Figures 2B and C). 
Functional loci were then mapped by testing 19 base-long siRNAs 
overlapping by one or two nucleotides upstream or downstream. Results 
shown in Tab. 1 demonstrate that locus 1 was efficient for the three 
morbilliviruses tested, although maximum efficacy for RPV required a 
single base shift within the locus towards the 5' end. Additionally, loci 6 
and 7 efficiently inhibited two out of three morbilliviruses tested (they 
have failed to inhibit MV replication; data not shown) and the efficacy of 
the loci 7 for RPV inhibition was also higher with a frame shift of one 
base downwards. 
Results of the silencing capacity of the Ad-shRNANl in infected cell 
culture dernonstrated that it clearly in11ibited the replication of PPRV. 
This inhibitory effect was characterized by a remarkable decrease of CPE 
(data not shown). Additionally, the virus titration showed a decrease in 
PPRV titres higher than 2 logs by the Ad-shRNANl in cell suspensions 
collected after 96 hours post-infection (Figure 3). This Ad-shRNANl will 
be tested soon in goats superinfected with PPRV. 
CONCLUSIONS 
We were able to identify loci in the N gene of MV, PPRV and RPV 
which showed very strong in vitro antiviral effect when inhibited by 
siRNA. Ali these siRNAs may be used alone or in association for 
targeting multiple viral regions to prevent the emergence of escape 
mutants. Currently, we are studying delivery methods of siRNAs to be 
applied in vivo. 
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Table 1. Mapping of loci. Results are expressed as percentages of inhibition 
(PI) of nucleoprotein expression as measured by flow cytometry. 
Positions 477-495 478-496 479-497 480-498 481-499 482-500 
NPPRVl NPPRVI- NPPRVI- NPPRVl-1 NPPRVl NPPRVl + l NPPRV1 +2 
3 2 
Pl value 7% 15% 78% 90% 24% 28% 
NPRPVl nt* NRPVl-2 NRPVl - 1 NRPVl NRPVJ + l nt 
PI value nt 35% 97% 70% 45% nt 
NMVl nt MVl-2 MVl-1 MVl MVl + l nt 
Pl value nt 35% 85% 90% 28% nt 
Positions 738-756 739-757 740-758 741-759 742-760 743-761 
NPPRV6 nt NPPRV6-2 NPPRV6-l NPPRV6 NPPRV6+ 1 NPPRV6+2 
Pl va lue nt 12% 35% 84% 55% 41 % 
NRPV6 nt NRPV6-2 NRPV6-l NRPV6 NRPV6+ 1 NRPV6+2 
Pl value nt 11 % 0% 85% 36% 40% 
Positions 896-914 897-915 898-916 899-917 900-918 901-919 
NPPRV7 nt NPPRV7-2 NPPRV7-l NPPRV7 NPPRV7+ 1 NPPRV7+2 
Pl value nt 35% 44% 87% 62% 40% 
NRPV7 nt NRPV7-2 NRPV7-I NRPV7 NRPV7+ 1 NRPV7+2 
Pl value nt 18% 36% 81 % 86% 49% 
*nt = not tested 
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Figure 3. Kinetic of PPRV multiplication in cell cultures transduced and 
non-transduced with the Ad-shRNANl. 
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